HILPDA: A Protein Regulating Pain Perception (G29923)

Target Name: HILPDA

NCBI ID: G29923

HILPDA

HILPDA: A Protein Regulating Pain Perception

HILPDA (C7orf68) is a protein that is found in the brain and is known for its role in the regulation of pain. It is a member of the C7 family of proteins, which are known as the G-protein-coupled receptors (GPCRs). GPCRs are a family of transmembrane proteins that play an important role in cellular signaling, and they are involved in a wide range of physiological processes, including sensory perception and pain modulation.

HILPDA is a 7-kDa protein that is expressed in the brain and is involved in the regulation of pain perception. It is localized to the diencephalon, which is the central part of the brain that is responsible for the processing of sensory information. HILPDA is involved in the GPCR signaling pathway, which is a well-established mechanism for the regulation of pain in the brain.

The GPCR signaling pathway is a complex system that involves the interaction of multiple proteins to regulate the activity of a GPCR. The pathway is composed of several steps, including the binding of a GPCR to its ligand, the activation of the protein by the ligand, and the conformational changes that occur as a result of the ligand binding.

HILPDA is involved in the GPCR signaling pathway by interacting with several other proteins that are involved in the pathway. For example, it is known to interact with the protein TrkB, which is a GPCR that is involved in the regulation of pain perception. TrkB is a 14-kDa protein that is expressed in various tissues, including the brain, and it is involved in the regulation of pain perception, anxiety, and other physiological processes.

HILPDA is also known to interact with the protein GprA2, which is a GPCR that is involved in the regulation of pain perception and inflammation. GprA2 is a 12-kDa protein that is expressed in various tissues, including the brain, and it is involved in the regulation of pain perception, anxiety, and inflammation.

In addition to its interactions with TrkB and GprA2, HILPDA is also known to interact with other proteins that are involved in the GPCR signaling pathway. For example, it is known to interact with the protein Pyvg, which is a GPCR that is involved in the regulation of pain perception and inflammation. Pyvg is a 10-kDa protein that is expressed in various tissues, including the brain, and it is involved in the regulation of pain perception, anxiety, and inflammation.

HILPDA is also involved in the regulation of pain perception by interacting with the protein Gsf-1, which is a GPCR that is involved in the regulation of pain perception and inflammation. Gsf-1 is a 7-kDa protein that is expressed in various tissues, including the brain, and it is involved in the regulation of pain perception, anxiety, and inflammation.

In conclusion, HILPDA is a protein that is involved in the regulation of pain perception. It is localized to the diencephalon and is involved in the GPCR signaling pathway. HILPDA interacts with several other proteins that are involved in the pathway, including TrkB, GprA2, Pyvg, Gsf-1, and others. These interactions suggest that HILPDA may be a drug target or biomarker for the regulation of pain perception. Further research is needed to confirm this potential and to determine the full range of its functions in the regulation of pain perception.

Protein Name: Hypoxia Inducible Lipid Droplet Associated

Functions: Increases intracellular lipid accumulation. Stimulates expression of cytokines including IL6, MIF and VEGFA. Enhances cell growth and proliferation

The "HILPDA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HILPDA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets